Manganese porphyrin-based treatment improves fetal-placental development and protects against oxidative damage and NLRP3 inflammasome activation in a rat maternal hypothyroidism model

• Published in: Redox biology Vol. 74; p. 103238
• Main Authors: dos Anjos Cordeiro, Jeane Martinha, Santos, Luciano Cardoso, Santos, Bianca Reis, de Jesus Nascimento, Acácia Eduarda, Santos, Emilly Oliveira, Barbosa, Erikles Macêdo, de Macêdo, Isabela Oliveira, Mendonça, Letícia Dias, Sarmento-Neto, José Ferreira, Pinho, Clarice Santos, Coura, Erick Teixeira dos Santos, Santos, Acácio de Sá, Rodrigues, Marciel Elio, Rebouças, Júlio Santos, De-Freitas-Silva, Gilson, Munhoz, Alexandre Dias, de Lavor, Mário Sérgio Lima, Silva, Juneo Freitas
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.08.2024; Elsevier
• Subjects: Animals; Antioxidant; Antioxidants - pharmacology; Disease Models, Animal; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress - drug effects; Female; Fetal Development - drug effects; Hypothyroidism - drug therapy; Hypothyroidism - metabolism; Inflammasome; Inflammasomes - metabolism; Manganese; Metalloporphyrin; Metalloporphyrins - pharmacology; NLR Family, Pyrin Domain-Containing 3 Protein - metabolism; Oxidative Stress - drug effects; Placenta; Placenta - drug effects; Placenta - metabolism; Placentation - drug effects; Pregnancy; Rat; Rats; Research Paper; Thyroid; Metalloporphyrin; Inflammasome; Placenta; Rat; Antioxidant; Thyroid
• ISSN: 2213-2317; 2213-2317
• DOI: 10.1016/j.redox.2024.103238

Oxidative stress (OS) and endoplasmic reticulum stress (ERS) are at the genesis of placental disorders observed in preeclampsia, intrauterine growth restriction, and maternal hypothyroidism. In this regard, cationic manganese porphyrins (MnPs) comprise potent redox-active therapeutics of high antioxidant and anti-inflammatory potential, which have not been evaluated in metabolic gestational diseases yet. This study evaluated the therapeutic potential of two MnPs, [MnTE-2-PyP]5+ (MnP I) and [MnT(5-Br-3-E-Py)P]5+ (MnP II), in the fetal-placental dysfunction of hypothyroid rats. Hypothyroidism was induced by administration of 6-Propyl-2-thiouracil (PTU) and treatment with MnPs I and II 0.1 mg/kg/day started on the 8th day of gestation (DG). The fetal and placental development, and protein and/or mRNA expression of antioxidant mediators (SOD1, CAT, GPx1), hypoxia (HIF1α), oxidative damage (8-OHdG, MDA), ERS (GRP78 and CHOP), immunological (TNFα, IL-6, IL-10, IL-1β, IL-18, NLRP3, Caspase1, Gasdermin D) and angiogenic (VEGF) were evaluated in the placenta and decidua on the 18th DG using immunohistochemistry and qPCR. ROS and peroxynitrite (PRX) were quantified by fluorometric assay, while enzyme activities of SOD, GST, and catalase were evaluated by colorimetric assay. MnPs I and II increased fetal body mass in hypothyroid rats, and MnP I increased fetal organ mass. MnPs restored the junctional zone morphology in hypothyroid rats and increased placental vascularization. MnPs blocked the increase of OS and ERS mediators caused by hypothyroidism, showing similar levels of expression of HIFα, 8-OHdG, MDA, Gpx1, GRP78, and Chop to the control. Moreover, MnPs I and/or II increased the protein expression of SOD1, Cat, and GPx1 and restored the expression of IL10, Nlrp3, and Caspase1 in the decidua and/or placenta. However, MnPs did not restore the low placental enzyme activity of SOD, CAT, and GST caused by hypothyroidism, while increased the decidual and placental protein expression of TNFα. The results show that treatment with MnPs improves the fetal-placental development and the placental inflammatory state of hypothyroid rats and protects against oxidative stress and reticular stress caused by hypothyroidism at the maternal-fetal interface.